InvestorsHub Logo
Followers 55
Posts 2608
Boards Moderated 0
Alias Born 02/04/2014

Re: trently post# 36083

Wednesday, 05/27/2015 5:24:06 PM

Wednesday, May 27, 2015 5:24:06 PM

Post# of 144812
It's a diversion tactic. If someone can discourage folks from looking at the science which is the future of the company and its future profits, they may be able to get folks to sell or reconsider their investment. Part of DD is being able to read through these deceitful tactics. I always look to other sources before making my choices. It always boils down to a personal choice and personal responsibility.

I will have all of my shares in tact when we do hear from Dr Von Hoff and all of my personal DD tells me that he will be sharing the miracle of Cell in a Box(R) technology. He was pretty excited to be working with CiaB over a year ago...

"The Nuvilex team presents us with a new tool to employ against the symptoms and invasive properties of this very challenging cancer," said Daniel D. Von Hoff, M.D., Chief Development Officer of TD2. "Our Pancreatic Cancer Research Team (PCRT) colleagues are enthusiastic to begin clinical trials with this approach."

Those clinical trials had positive results and lead to extented trials which will result in 2 different human trials for 2 different treatments to start in 3q & 4q of this year. A very significant outcome which some folks would rather other investors to disregard.

http://www.pharmacytebiotech.com/pharmacyte-biotech-on-track-to-commence-clinical-trials/

http://www.td2inc.com/news/nuvilex-selects-translational-drug-development-td2-to-advanc
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PMCB News